Analysts Set Medexus Pharmaceuticals Inc. (TSE:MDP) Target Price at C$5.49

Shares of Medexus Pharmaceuticals Inc. (TSE:MDP) have been given a consensus rating of “Buy” by the seven analysts that are currently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating, one has given a buy rating and four have given a strong buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is C$5.49.

Several equities research analysts have recently commented on MDP shares. Ventum Financial lifted their target price on Medexus Pharmaceuticals from C$5.00 to C$6.25 and gave the company a “buy” rating in a research note on Thursday, January 30th. Stifel Canada lowered Medexus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 6th. Stifel Nicolaus cut Medexus Pharmaceuticals from a “buy” rating to a “hold” rating and dropped their price objective for the stock from C$6.00 to C$3.45 in a report on Friday, February 7th. Ventum Cap Mkts raised shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 17th. Finally, Raymond James raised shares of Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price target for the company in a research note on Wednesday, January 8th.

Medexus Pharmaceuticals Price Performance

MDP stock opened at C$2.87 on Friday. The stock has a market capitalization of C$64.25 million, a price-to-earnings ratio of 13.72 and a beta of 1.96. The business has a fifty day moving average price of C$3.58 and a 200 day moving average price of C$2.88. Medexus Pharmaceuticals has a fifty-two week low of C$1.47 and a fifty-two week high of C$5.56.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.